CAJ | 학술논문

目的：评价吉西他滨联合顺铂化疗对进展食管癌患者的疗效及毒副反应。方法选取我院2009年10月至2011年10月收治的50例进展期食管癌患者资料，病理证实为鳞状细胞癌。吉西他滨1000 mg/m2d 1、8；顺铂25 mg/m2d 2～5；21 d 为1周期，化疗期间常规积极对症支持治疗，每个患者完成至少2周期化疗后评价疗效。结果50例均接受至少2周期的化疗，共完成132个周期。病例均可评价疗效及不良反应，部分缓解（PR）19例，有效率51.4%；中位疾病进展时间5.9个月，中位生存时间为11.2个月，主要不良反应为恶心、呕吐、血小板减少、粒细胞减少等。结论吉西他滨联合顺铂化疗对晚期食道癌效果好，患者的安全性和遵从性好，可以作为治疗晚期食管鳞状细胞癌化学治疗的选择方案。
목적：평개길서타빈연합순박화료대진전식관암환자적료효급독부반응。방법선취아원2009년10월지2011년10월수치적50례진전기식관암환자자료，병리증실위린상세포암。길서타빈1000 mg/m2d 1、8；순박25 mg/m2d 2～5；21 d 위1주기，화료기간상규적겁대증지지치료，매개환자완성지소2주기화료후평개료효。결과50례균접수지소2주기적화료，공완성132개주기。병례균가평개료효급불량반응，부분완해（PR）19례，유효솔51.4%；중위질병진전시간5.9개월，중위생존시간위11.2개월，주요불량반응위악심、구토、혈소판감소、립세포감소등。결론길서타빈연합순박화료대만기식도암효과호，환자적안전성화준종성호，가이작위치료만기식관린상세포암화학치료적선택방안。
Objective To evaluate the gemcitabine combined cisplatin chemotherapy curative effect and adverse reaction of progression in patients with esophageal cancer. Methods Select our hospital between October 2009 and October 2009 of the 50cases of patients with advanced esophageal cancer data, confirmed by pathology squamous cell carcinoma. Gemcitabine 1000 mg/m2d 1,8;Cisplatin(25 mg/m2d 2-5;21 d to 1cycle,conventional actively support therapy during chemotherapy,after each complete at least 2 cycles of chemotherapy in patients with therapeutic evaluation. Results 50 cases were accepted at least 2cycles of chemotherapy,completed 132 cycles of chemotherapy.Cases can evaluate curative effect and adverse reaction, partial response(PR)19cases,the effective rate was 51.4%;The median time of disease progression of 5.9 months,the median survival time was 11.2 months,major adverse reactions of nausea,vomiting,thrombocytopenia,and granulocytopenia. Conclusion Gemcitabine combined cisplatin chemotherapy for advanced esophageal cancer effect is good,the security and the patients compliance is good,can be used as a treatment of advanced esophageal squamous carcinoma.